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Background: Plasma homocysteine (Hcy) levels are increased in patients with Parkinson’s 
disease (PD) undergoing levodopa treatment. We measured the Hcy levels in PD patients 
and assessed the relationship between Hcy level and features of PD, cognitive function and 
vitamin B status. Methods: Concentrations of Hcy, vitamin B12 and folate were measured 
in 33 PD patients and 41 normal control individuals. Mini-mental Status Examination 
(MMSE) was assessed in all subjects. In PD patients, Hoehn & Yahr stage and Unified 
Parkinson Disease Rating Scale (UPDRS) motor scores were also examined. Results: 
Plasma Hcy levels were lower in PD patients than in control individuals. Hcy level was 
inversely correlated with vitamin B12 and folate levels in the PD group but not in control 
individuals. Age, symptom duration, UPDRS motor scores, MMSE score, levodopa dose 
and duration of treatment did not differ between patients with Hcy >14 μmol/L and those 
with Hcy <14 μmol/L. Conclusions: Plasma Hcy levels were increased in PD patients 
with levodopa treatment and were related to vitamin B level. These results indicate that 
vitamin supplementation may be beneficial in levodopa-treated PD patients, although hy-
perhomocysteinemia did not affect the motor and cognitive status of PD patients. 
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Introduction 
 
Plasma homocysteine (Hcy) levels are increased in Parkinson’s disease (PD) patients 
with levodopa treatment compared with control individuals.1-9 Increased Hcy levels in PD 
patients result from the metabolism of levodopa. S-adenosylmethionine (SAM), which is the
methyl donor of catechol-O-methyltransferase (COMT), forms S-adenosylhomocysteine 
(SAH), which is converted to Hcy.9 
Hcy has various neuronal and endothelial cellular toxicities,10-12 and hyperhomocystei-
nemia is related to cardiovascular, cerebrovascular,13,14 and neurodegenerative disease.1,2,15-17
Therefore, increased Hcy levels have been suggested to have a role in progression of 
disease or development of cognitive impairment in PD patients. Several previous studies 
have investigated the relationship between hyperhomocysteinemia and vitamin B status in 
PD patients and have proposed that vitamin supplementation might prevent the possible 
harmful effects of Hcy in PD patients.18-21 We compared Hcy and vitamin B levels in PD 
patients with those in normal control in-dividuals and evaluated the relationship between 
Hcy level and clinical features in PD patients.  
 
Subjects and Methods 
 
Subjects 
Thirty-three patients with PD who were treated with levodopa for at least for 3 years and 
41 age-matched control individuals with no history of neurological disease were included 
in this study. All PD patients were diagnosed according to UK Brain Bank criteria and 
showed a good response to levodopa treatment. 
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Assessment of subjects 
Concentrations of Hcy, vitamin B12 and folate were meas-
ured by competitive immunoassays assessing direct chemi-
luminescence in the plasma of the subjects; plasma was ob-
tained from the centrifuged blood. Mini-mental status exam-
ination (MMSE) was evaluated in all subjects. In the PD 
group, symptom duration, treatment duration, Hoehn & Yahr 
stage, Unified Parkinson Disease Rating Scale (UPDRS) 
motor score and levodopa dose were also assessed.  
 
Data analysis 
Laboratory measures including Hcy, vitamin B12 and folate 
concentrations and MMSE scores were compared between 
patients and control individuals using t-tests. The difference 
of sex ratio between the groups was analyzed using Chi-square 
tests. In addition, clinical characteristics were also compared 
between PD patients with Hcy level greater than 14 μmol/L 
and those with Hcy level less than 14 μmol/L using a t-test. 
Linear regression analysis was used to evaluate the correla-
tions between Hcy concentration and vitamin B12 concentra-
tion, folate concentration and clinical parameters, both in PD 
patients and control individuals. p value <0.05 was consider-
ed statistically significant.  
 
Results 
 
Hcy level in PD patients and controls 
The demographic characteristics of the PD patients and 
control individuals are listed in Table 1. The mean age of the 
PD patients and control individuals was similar (63.6±8.0 
years, range 47-80 years, vs. 65.4±7.8 years, range 48-77 
years). PD patients had a higher Hcy level than the control 
individuals (p<0.05), although there were no differences in 
MMSE score or folate level between the groups. Vitamin B12 
level was lower in the PD patients compared with the control 
group, but the difference was not significant (p=0.06). In the 
control group, Hcy level was not correlated with vitamin B12 
or folate levels; however, it was inversely correlated with 
both vitamin B12 and folate levels in PD patients (F=6.670, 
r2=0.177, p<0.05, F=11.341, r2=0.268, p<0.05, for vitamin 
B12 and folate levels, respectively)(Figure 1). 
Clinical characteristics and vitamin status in PD 
patients with Hcy >14 μmol/L and Hcy <14 μmol/L 
In the PD group, there were no differences in age, symp-
tom duration, UPDRS motor score, MMSE score, levodopa 
dose and duration of levodopa treatment between patients 
with Hcy >14 μmol/L and those with Hcy <14 μmol/L. 
Vitamin B12 and folate levels were decreased in patients with 
Hcy >14 μmol/L compared with those with Hcy <14 μmol/L 
(Table 2).  
 
Discussion 
 
Our study showed that Hcy levels are increased in levo-
dopa-treated PD patients compared with normal control in-
dividuals. This is in agreement with findings from previous 
studies of hyperhomocysteinemia in PD patients. In a pre-
vious prospective study, levodopa was shown to increase Hcy 
levels in PD patients,5 whereas Hcy levels in untreated PD 
patients were similar to those of normal control individuals.22 
Therefore, increased Hcy levels in levodopa-treated PD pa-
tients might be caused by levodopa treatment rather than by 
the disease itself. 
There were no differences in age, symptom duration, 
UPDRS score, duration of levodopa treatment and levodopa 
dose between PD patients with Hcy level >14 μmol/L and 
those with Hcy <14 μmol/L. Experimental studies found that 
hyperhomocysteinemia was associated with neurotoxicity in 
neurodegenerative disorders.12,23,24 However, most previous 
clinical studies of hyperhomocysteinemia in PD patients fail-
ed to show a relationship between increased Hcy levels with 
Table 1. Demographic characteristics, and Hcy, vitamin B12 and 
folate levels in PD patients and control individuals 
 PD patients Control individuals p value 
Age (years) 63.5±7.80 65.4±7.80 0.30 
Gender (M/F) 10/23 12/29 0.92 
MMSE 23.5±4.70 24.8±3.90 0.17 
Hcy (µmol/L) 13.6±7.30 11.0±2.90 <0.05 
Vitamin B12 (pg/mL) 716.6±406.2 883.6±320.2 0.06 
Folate (ng/mL) 8.5±4.0 10.2±4.80 0.12 
Hcy: homocysteine, MMSE: Mini-mental status examination, PD: 
Parkinson’s disease. 
 
Figure 1. Hcy level was inversely cor-
related with vitamin B12 (A) and folate 
levels (B) in PD patients (F=6.670, r 2= 
0.177, p<0.05, F=11.341, r2=0.268, p< 
0.05, respectively). Hcy: homocysteine,
PD: Parkinson’s disease. 
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severity or duration of the disease,1-7 similar to our study. In 
addition, a 2-year follow-up study demonstrated similar cli-
nical deterioration in PD patients with increased Hcy levels 
and those with normal Hcy levels.10 These results indicate 
that increased Hcy levels in PD patients are not enough toxic 
to affect the disease severity of such patients. A long-term 
prospective study may determine the effects of increased Hcy 
levels on progression of neurodegeneration in PD patients. 
Epidemiological studies have shown that plasma Hcy level 
is correlated with cognitive function in normal elderly indi-
viduals and that plasma Hcy level is increased in patients 
with Alzheimer’s disease (AD). PD patients with increased 
Hcy level showed worse cognitive performance compared 
with those with normal Hcy levels.6,8,22,25 Our data showed no 
significant difference in MMSE score between patients with 
Hcy >14 μmol/L and those with Hcy <14 μmol/L. However, 
mean MMSE scores tend to be lower in patients with Hcy 
>14 μmol/L than in those with Hcy <14 μmol/L (21.9 vs. 24.3, 
respectively, p=0.17). PD patients in the present study were 
not compatible with overt dementia. This is in agreement 
with the results of a recent study that showed that Hcy is not 
associated with cognitive function in non-demented PD pa-
tients.26 Although MMSE score is a useful tool for the screen-
ing of dementia patients, it cannot evaluate the various cog-
nitive domains in detail, particularly those of frontal-execu-
tive function. Frontal-executive dysfunction is a prominent 
finding of dementia in PD patients, and can sometimes be 
seen in PD patients without dementia. There-fore, detailed 
neuropsychological tests, including frontal-executive function 
tests, will be needed to evaluate significant differences in cog-
nitive performance between patients with hyperhomocystei-
nemia and those with a normal Hcy level. 
The vitamin B12 level was decreased in PD patients com-
pared with control individuals, although the difference was 
not significant. In addition, vitamin B12 and folate levels were 
lower in PD patients with hyperhomocysteinemia compared 
with those without hyperhomocysteinemia. Re-methylation 
of Hcy involves vitamin B12- and folate-dependent path-
ways;9 hence, hyperhomocysteinemia might reduce the vita-
min B12 level. The inverse correlation between Hcy level and 
vitamin status supports the hypothesis that Hcy levels are 
affected by the vitamin status in PD patients receiving levo-
dopa treatment. Hcy levels in normal control individuals were 
not correlated with vitamin B12 or folate levels, indicating that 
Hcy levels are dependent on the vitamin status in patients with 
hyperhomocysteinemia, including PD patients undergoing le-
vodopa treatment. Although this study failed to show a rela-
tionship between hyperhomocysteinemia and motor and cog-
nitive status of PD patients, the differences in vitamin status 
between PD patients and control individuals suggest a need 
for vitamin supplementation in levodopa-treated PD patients, 
in agreement with the results of previous studies.18-21 
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